Embed Size (px)
Citation preview
November 12, 2019
To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code -532523
Dear Sir/Madam,
Subject: Press Release
To The Manager,
~$Biocon BioGon Limited 20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417
www.biocon.com
National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Sandra Kurla Complex Mumbai- 400 050 Scrip Symbol- Biocon
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled "Biocon Features in the Prestigious ASIA JP ELITE List for the Fourth Consecutive Year".
The above information will also be available on the website of the Company at www.biocon.com.
Kindly take the same on record and acknowledge.
Thanking You,
Yours faithfully, For Biocon Limited
Mayank Verma Company Secretary & Compliance Officer
Enclosed: Press Release
<$siocon <$ Biocon Biologics
Press Release
Biocon Features in the Prestigious ASIA IP ELITE List for the
Fourth Consecutive Year
Biocon Biologics Debuts on the ASIA IP ELITE 2019 List
Bengaluru, Karnataka, India, November 12, 2019
Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced that it
has been recognised as the ASIA IP ELITE for the fourth year in a row and its wholly-owned
subsidiary Biocon Biologics makes its debut on this prestigious list in 2019 by the IP Business
Congress Asia {IPBC Asia) for robust Intellectual Property (IP) management and consistent IP
value creation.
In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on
the prestigious ASIA IP ELITE list. This year i1ts subsidiary Biocon Biologics, a fully integrated
'pure play' global biosimilars company, dedicated to developing high quality, affordable
biosimilars for patients globally, has made it to the ASIA IP ELITE 2019 list, reinforcing
Biocon's commitment towards creating intellectual wealth and value for its stakeholders.
Biocon Biologics received this Award at the recently concluded IP Business Congress Asia in
Tokyo, Japan.
Dr. Christiane Hamacher, Chief Executive Officer, Biocon Biologics, said: "We are pleased
that Biocon Biologics has been inducted into the Asia IP ELITE 2019 List. This recognition is
an endorsement of Biocon Group's strategy of value creation through innovation and IP to
serve patient needs across the world. Biocon Biologics has a strong portfolio of Intellectual
Property assets with granted patents and trademarks. Our IP team has demonstrated a
sustained commitment to building best-in-class in-house IP function focussed on continuous
excellence in IP value creation."
Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan,
several with Sandoz, and many being developed independently. The company's therapeutic
basket includes molecules from diabetes, oncology, immunology, dermatology,
ophthalmology, neurology, rheumatology and inflammatory diseases.
1
~$ Biocon Biologics
The companies selected as the Asia IP Elite 2019 were honoured at the latest edition of the
IP Business Congress Asia, which is hosted by Intellectual Asset Management, the publishers
of the world's leading IP magazine lAM.
About Biocon Biologics:
Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company.
Biocon Biologics is engaged in developing high quality, affordable biosimilars aimed at expanding
patient access to cutting-edge class of therapies across the world. It is uniquely positioned as a fully
integrated 'pure play' biosimilars organization globally. Biocon Biologics aspires to transform patient
lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of
biosimilars under global clinical development with three of these commercialized in developed
markets like EU, Australia, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules,
including 11 partnered with Mylan, several with Sandoz and many being developed independently.
About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE ld: BIOCON, ISIN ld: INE376G01013) is
an innovation-led global biopharmaceuticals company committed to enhance affordable access to
complex therapies for chronic conditions like diabetes, cancer and autoimmune. It is a leading global
player for APis including statins, immunosuppressants and specialty molecules. Biocon has developed
and commercialized novel biologics, biosimilars, and complex small molecule APis in India and several
key global markets as well as generic formulations in the U.S. and Europe. It also has a pipeline of
promising novel assets in immunotherapy under development. Biocon is committed to pursue the
path of innovation to develop products that have the potential to benefit a billion lives. Biocon
Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated 'pure play'
biosimilars organization in the world and aspires to transform patient lives through innovative and
inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical
development with three of these commercialized in developed markets like EU, Australia, U.S. and
Japan.
FOR MORE INFORMATION
MEDIA RELATIONS Seema Ahuja Riddhima Jaitly Sr. VP & Global Head, Corporate Communications Executive, Corporate Communications V+91 80 2808 2222 • +9180 2808 2183 J +9199723 17792 J +91 9742197514
[8] [email protected] [8] riddhima.ja iti:'[email protected]
2
